Takeda CMO reports 112,629 ADS holdings
Takeda Pharmaceutical’s Chief Medical Officer, Farajallah Awny Samaan Botros, reported his initial shareholdings in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Takeda Pharmaceutical’s Chief Medical Officer, Farajallah Awny Samaan Botros, reported his initial shareholdings in the company. He holds 112,629 American Depositary Shares directly, including 73,220 restricted stock units that convert into ADSs as they vest on scheduled dates from July 1, 2026 through July 1, 2028.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | American Depositary Shares | -- | -- | -- |
Footnotes (1)
- F1. Includes 73,220 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (36,562 shares), July 1, 2027 (22,560 shares) and July 1, 2028 (14,098 shares).
Key Figures
Key Terms
restricted stock units financial
RSUs financial
vest financial
AI-generated analysis. How Rhea-AI works. Not financial advice.